Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer

Gastric cancer (GC) is the third cause of cancer-related death worldwide. Patients with unresectable GC can be treated with chemotherapy such as paclitaxel, which is a microtubule stabilizer. The use of nanoparticle albumin-bound paclitaxel (nab-ptx) avoids hypersensitivity reactions due to the abse...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 2019-10, Vol.84 (4), p.669-677
Main Authors: Roviello, G., Conter, F. U., Mini, E., Generali, D., Traversini, M., Lavacchi, D., Nobili, S., Sobhani, N.
Format: Article
Language:English
Subjects:
Albumin
Albumin-Bound Paclitaxel - pharmacology
Cancer
Cancer Research
Chemotherapy
Gastric cancer
Humans
Hypersensitivity
Immunotherapy
Medicine
Medicine & Public Health
Monoclonal antibodies
Nanoparticles
Nanoparticles - therapeutic use
Oncology
Paclitaxel
Patients
Pharmacology/Toxicology
Review Article
Solvents
Stomach Neoplasms - drug therapy
Targeted cancer therapy
Tubulin Modulators - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gastric cancer (GC) is the third cause of cancer-related death worldwide. Patients with unresectable GC can be treated with chemotherapy such as paclitaxel, which is a microtubule stabilizer. The use of nanoparticle albumin-bound paclitaxel (nab-ptx) avoids hypersensitivity reactions due to the absence of solvent needed to dissolve paclitaxel and it can be administered at higher doses. The ABSOLUTE randomized phase-3 clinical trial showed the non-inferiority of the nab-ptx used every week compared to the solvent-based paclitaxel used every week. This review describes the current advancements of the use of nab-ptx in GC in preclinical and clinical study investigations. The possibility of combining nab-ptx with other medications to improve response of patients to their specific molecular needs will also be debated.
ISSN:0344-5704
1432-0843
DOI:10.1007/s00280-019-03887-2